- Home
- CRNX vs IMVT Comparison
CRNX vs IMVT Comparison
Compare CRNX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- IMVT
- Stock Information
- Founded
- CRNX 2008
- IMVT 2018
- Country
- CRNX United States
- IMVT United States
- Employees
- CRNX N/A
- IMVT N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRNX Health Care
- IMVT Health Care
- Exchange
- CRNX Nasdaq
- IMVT Nasdaq
- Market Cap
- CRNX 2.8B
- IMVT 2.7B
- IPO Year
- CRNX 2018
- IMVT N/A
- Fundamental
- Price
- CRNX $31.75
- IMVT $18.12
- Analyst Decision
- CRNX Strong Buy
- IMVT Buy
- Analyst Count
- CRNX 8
- IMVT 10
- Target Price
- CRNX $74.86
- IMVT $40.14
- AVG Volume (30 Days)
- CRNX 725.8K
- IMVT 1.3M
- Earning Date
- CRNX 08-07-2025
- IMVT 08-05-2025
- Dividend Yield
- CRNX N/A
- IMVT N/A
- EPS Growth
- CRNX N/A
- IMVT N/A
- EPS
- CRNX N/A
- IMVT N/A
- Revenue
- CRNX $760,000.00
- IMVT N/A
- Revenue This Year
- CRNX $402.02
- IMVT N/A
- Revenue Next Year
- CRNX $771.03
- IMVT N/A
- P/E Ratio
- CRNX N/A
- IMVT N/A
- Revenue Growth
- CRNX N/A
- IMVT N/A
- 52 Week Low
- CRNX $24.10
- IMVT $12.72
- 52 Week High
- CRNX $62.53
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- CRNX 57.94
- IMVT 68.50
- Support Level
- CRNX $28.98
- IMVT $16.88
- Resistance Level
- CRNX $32.49
- IMVT $17.10
- Average True Range (ATR)
- CRNX 1.24
- IMVT 0.71
- MACD
- CRNX 0.30
- IMVT 0.16
- Stochastic Oscillator
- CRNX 90.54
- IMVT 99.65
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.